Nektar Therapeutics: 4.0 Billion USD Revenue Potential – Why a New Biologic Drives the Price Target to 130 USD
Reading Time: 3 minutes
Leerink analyst assigns an "Outperform" rating with an ambitious price target of 130 USD for Nektar Therapeutics (NKTR) . The biological product Rezpegaldesleukin offers a gross peak sales potential of 4.0 billion USD due to its unique T cell mechanism of action. Current liquidity of over 1.023 billion USD secures the funding for the ongoing Phase 3 studies. Business Model and Growth Trends in Immunology Nektar Therapeutics operates as a biopharmaceutical company focusing on innovative therapies in the field of immunology. The business...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
